TITLE

FAST STATS

PUB. DATE
March 2016
SOURCE
Healthcare Purchasing News;Mar2016, Vol. 40 Issue 3, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Statistics are given in the healthcare industry as of March 2016, including the number of countries and territories in the Americas dealing with local Zika virus transmission, the number of laboratory-confirmed cases of Zika virus, and the emergency funding requested by U.S. President Barack Obama to the U.S. Congress to deal with the Zika virus.
ACCESSION #
113400473

 

Related Articles

  • Poor countries should be asked to pay towards health schemes. Coombes, Rebecca // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;10/8/2011, Vol. 343 Issue 7826, p716 

    The article reports on the statements of David Heymann, chairman of the Health Protection Agency in Great Britain, at the 2011 Global Health Conference regarding the need for low income countries to make financial contribution for their health programmes.

  • Open pricing of vaccines would help poor countries too. Hecht, Robert; Kaddar, Miloud; Schmitt, Sarah // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;11/26/2011, Vol. 343 Issue 7833, p1101 

    The author discusses the importance of price transparency of vaccines, especially for the poor countries. The author states that vaccine prices' openness is important for the middle income nations that are seeing themselves in the dark in talking with the producers for acquiring new vaccines....

  • Policy Watch. Global health challenges spur development of vaccines at home and abroad. Wechsler, Jill // Formulary;Oct2011, Vol. 46 Issue 10, p450 

    The article reports on an increase which has been seen in 2011 in research on and the development of vaccines in the U.S. and across the globe as a result of global health challenges related to diseases such as influenza, AIDS and cancer. A February 2011 ruling from the U.S. Supreme Court which...

  • Meeting of the Strategic Advisory Group of Experts on immunization, November 2012 - conclusions and recommendations.  // Weekly Epidemiological Record;1/4/2013, Vol. 88 Issue 1, p1 

    Information about several discussions at the Meeting of the Strategic Advisory Group of Experts on immunization held November 6-8, 2012 in Geneva, Switzerland is presented. Topics included a report from the World Health Organization (WHO) Department of Immunization, Vaccines and Biologicals; a...

  • Polio crisis. Mackenzie, Deb // New Scientist;9/18/2010, Vol. 207 Issue 2778, p01 

    The article discusses the global impact of a shortage of funds on the polio eradication program, the Global Polio Eradication Initiative (GPEI), such as the reduction of polio vaccination and surveillance in at-risk countries.

  • Silver lining for Indian vaccine industry. Ella, Krishna // BioSpectrum;Jul2013, Vol. 11 Issue 7, p26 

    The article focuses on the status of Indian vaccine industry as of July 2013. Topics discussed include the approval of the World Health Organization (WHO) to vaccine clearance procedure of the National Regulatory Authority which is considered as one of the most significant development in the...

  • Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines.  // Weekly Epidemiological Record;10/4/2002, Vol. 77 Issue 40, p331 

    Focuses on the information and recommendations on the vaccines represented in the Expanded Programme on Immunization of the World Health Organization (WHO). Background information and vaccines for meningococcal meningitis and septicemia; Concerns addressed by position papers released by WHO;...

  • Alliance aims to immunize children.  // Nation's Health;Jun2000, Vol. 30 Issue 5, p14 

    Reports on the Global Alliance for Vaccines and Immunization and its goal of reaching unimmunized children in the world's poor countries. Total amount granted by the government to the alliance's program; Uses of the alliance's vaccine fund.

  • Evolving vaccines.  // Nature Medicine;Oct1999, Vol. 5 Issue 10, p1089 

    Editorial. Explores strategies to enhance the global effectiveness and availability of vaccination programs. Costs of vaccine development; Initiatives to improve vaccination in developing countries; Aims of the Global Alliance for Vaccines and Immunization.

  • Why we must pay more. Rappuoli, Rino // New Scientist;8/31/2002, Vol. 175 Issue 2358, p25 

    Comments on the reduction of price for vaccines. Inauguration of the Global Alliance for Vaccines and Immunization; Disparity between the power of vaccines and the willingness of the people to invest in it; Renewed awareness of the importance of vaccines.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics